Mackenzie Financial Corp Novo Nordisk A S Transaction History

Mackenzie Financial Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 13, 2020	BUY	$49.86 - $58.26 $69,804 - $81,564	1,400 Added 15.73%	10,300 $596,000
Q3 2019 Nov 14, 2019	BUY	$47.54 - $53.43 $99,834 - $112,203	2,100 Added 30.88%	8,900 $460,000
Q2 2019 Aug 14, 2019	BUY	$46.79 - $52.47 $318,172 - $356,796	6,800 New	6,800 $347,000
Q4 2018 Feb 06, 2019	SELL	$41.54 - $47.25 $1.45 Million - $1.65 Million	-34,993 Closed	0 $0
Q3 2018 Nov 15, 2018	SELL	$46.76 - $51.24 $13,653 - $14,962	-292 Reduced 0.83%	34,993 $1.65 Million
Q2 2018 Aug 13, 2018	BUY	$44.29 - $50.42 $127,998 - $145,713	2,890 Added 8.92%	35,285 $1.63 Million
Q1 2018 May 14, 2018	BUY	$48.49 - $58.14 $428,215 - $513,434	8,831 Added 37.48%	32,395 $1.6 Million
Q4 2017 Feb 13, 2018	BUY	$47.53 - $53.73 $220,634 - $249,414	4,642 Added 24.53%	23,564 $1.27 Million
Q3 2017 Nov 13, 2017	SELL	$41.15 - $49.22 $852,998 - $1.02 Million	-20,729 Reduced 52.28%	18,922 $911,000
Q2 2017 Aug 14, 2017	BUY	N/A	39,651	39,651 $1.7 Million

1,955

318M

5.49M

7.78M

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $193B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Mackenzie Financial Corp with notifications on news.